Search clinical trials for: Dabigatran etexilate mesylate

Total 1938 results

The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients (EMBRAVE-001)

Triple Negative Breast Cancer

China
National Cancer Institute (NCI)

Completed

S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Head and Neck Cancer

United States
Merz Pharmaceuticals GmbH

Completed

Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

Subjective Tinnitus

United States, Austria, Germany, Brazil, Mexico
Merz Pharmaceuticals GmbH

Completed

Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus

Subjective Tinnitus

Belgium, Czech Republic, France, Poland, South Africa, Netherlands
Seoul National University Hospital

Recruiting

Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer (ESPERO)

Advanced Breast Cancer

Korea, Republic of
InteKrin Therapeutics, Inc.

Completed

A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus

Diabetes Mellitus, Type II

United States
Korea University

Unknown

Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk

Atrial Fibrillation | Thromboembolism
Boehringer Ingelheim

Terminated

Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery

Venous Thromboembolism | Arthroplasty, Replacement

Austria
Cancer Research UK
Latus Therapeutics

Terminated

A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) (SPIKE-1)

COVID-19 Infection

United Kingdom
Celgene

Completed

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Hepatic Impairment

United States
Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Kyunghee University Medical Center

Unknown

Pleotropic Effect of New Oral Anticoagulants

Atrial Fibrillation

Korea, Republic of
Boehringer Ingelheim

Completed

Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention

Heart Catheterization

Netherlands
Integrative Skin Science and Research
Actera

Not yet recruiting

The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation

Hyperpigmentation | Acne | Post-inflammatory Hyperpigmentation
Ball State University

Completed

Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging

Aging | Endothelial Dysfunction | Arterial Stiffness | Cardiovascular Function

United States
Zhejiang Cancer Hospital

Not yet recruiting

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Metastatic Breast Cancer

China
UConn Health
National Institute on Aging (NIA); University of Connecticut

Not yet recruiting

The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults (Mito-Frail)

Frailty | Aging | Mild Cognitive Impairment

United States
Eisai Inc.

Completed

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

Breast Cancer

United States
Peking University Third Hospital

Recruiting

A Clinical Study to Evaluate the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Healthy Volunteers and Renal Impairment Patients

Chronic Kidney Disease

China
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran Etexilate

Healthy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body

Chronic Myeloid Leukemia

China
Boehringer Ingelheim

Completed

PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin

Atrial Fibrillation

United States, Denmark, Sweden
Medical University of Gdansk
Institute of Cardiology, Warsaw, Poland; Medical University of Silesia; Pomeranian... and other collaborators

Recruiting

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI (ADONIS-PCI)

Atrial Fibrillation | Acute Coronary Syndrome | Antithrombotic Therapy | Percutaneous Coronary Interventions

Poland
Sagent Pharmaceuticals Inc.

Completed

Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)

COVID-19

United States
Nova Scotia Health Authority

Withdrawn

Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy

Venous Thromboses
Esanex Inc.
National Cancer Institute (NCI)

Completed

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Lymphoma | Leukemia | Solid Tumor Malignancy | Lymphoid Malignancy (Lymphoma and CLL)

United States
Boehringer Ingelheim

Completed

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects

Healthy

Japan
University of Roma La Sapienza

Recruiting

Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk Patients (INTERMITTENT)

Atrial Fibrillation | Ischemic Heart Disease

Italy
Yale University

Completed

Camostat Mesylate in COVID-19 Outpatients

COVID-19

United States
Pfizer

Withdrawn

NOAC Portuguese Real World Study

Stroke | Systemic Embolism | Major Bleeding
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

HER2-negative Breast Cancer

China
Eisai Co., Ltd.

Completed

Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)

Inoperable or Recurrent Breast Cancer

Japan
Merz Pharmaceuticals GmbH

Completed

Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus

Nystagmus, Acquired | Nystagmus, Congenital Idiopathic

United Kingdom
Second Affiliated Hospital of Soochow University

Active, not recruiting

A Clinical Study of Dihydroergotine Mesylate Extended-release Tablets for the Treatment of Drooling in Parkinson's Disease.

Salivation in Parkinson's Disease

China
Eisai Inc.

Completed

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Locally Recurrent | Metastatic Breast Cancer ( HER2 Negative)

United States
Pfizer

Completed

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

Healthy Participants

United States
Zuyderland Medisch Centrum
Boehringer Ingelheim

Recruiting

Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI (RE-DUAL PCI)

Myocardial Infarction | Myocardial Ischemia | Coronary Artery Disease | Atrial Fibrillation

Netherlands
Boehringer Ingelheim

Completed

Investigation of the Impact of Concomitant Use of Multiple Doses of Clopidogrel With Multiple Doses of Dabigatran Etexilate on the Pharmacokinetic and Pharmacodynamic Parameters in Healthy Male Subjects

Healthy
Wuhan Union Hospital, China
Yichang Humanwell Pharmaceutical Co., Ltd., China

Recruiting

PK/PD Properties and Safety of Remazolam Besylate for Injection in ICU Patients With Impaired Renal Function

Mechanically Ventilated Patients

China
Institut Bergonié
Novartis

Terminated

Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response (MIM)

Leukemia, Myeloid, Chronic-Phase

France
University of Oklahoma

Terminated

Study of Eribulin in Children With Cancer to Determine Safety (ERIBULIN)

Lymphoma | Solid Tumors | Pediatric Cancer

United States
Novartis Pharmaceuticals

Completed

Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate (Radix)

Progressive Gastrointestinal Stromal Tumor

Germany
Stanford University

Completed

Imatinib in Systemic Sclerosis

Scleroderma, Systemic

United States
Novartis Pharmaceuticals

Completed

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Life Threatening Diseases
UNICANCER

Completed

Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

Desmoid Tumor

France
University Hospital, Bordeaux
Novartis; Ministry of Health, France

Completed

Efficacy and Safety of Imatinib in Scleroderma (SCLEROGLIVEC)

Scleroderma, Systemic | Scleroderma, Localized

France
Maisonneuve-Rosemont Hospital
Hippocrate Research & Development

Unknown

Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumors

Canada
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Salivary Gland Cancer

Head and Neck Cancer

United States, Canada
Novartis

Completed

STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia

Leukemia

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

Sarcoma | Childhood Malignant Fibrous Histiocytoma of Bone

United States

3

Subscribe